menu
    • menu
    [{"orgOrder":0,"company":"NX Development Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NX Development Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NX Development Corp \/ Undisclosed"},{"orgOrder":0,"company":"NX Development Corp","sponsor":"NX Development Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NX Development Corp \/ NX Development Corp","highestDevelopmentStatusID":"6","companyTruncated":"NX Development Corp \/ NX Development Corp"},{"orgOrder":0,"company":"NX Development Corp","sponsor":"NX Development Corp","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NX Development Corp \/ NX Development Corp","highestDevelopmentStatusID":"8","companyTruncated":"NX Development Corp \/ NX Development Corp"},{"orgOrder":0,"company":"NX Development Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NX Development Corp \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NX Development Corp \/ Undisclosed"},{"orgOrder":0,"company":"NX Development Corp","sponsor":"Costas Hadjipanayis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Aminolevulinic Acid HCl","moa":"DNA","graph1":"Oncology","graph2":"Phase II","graph3":"NX Development Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NX Development Corp \/ Costas Hadjipanayis","highestDevelopmentStatusID":"8","companyTruncated":"NX Development Corp \/ Costas Hadjipanayis"}]

    Find Clinical Drug Pipeline Developments & Deals by NX Development Corp

    Menu

    NX Development Corp

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : University of Colorado, Denver

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            5-AminoLevulinic Acid Aided Resection Margins in Sarcoma

                            Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Sarcoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 26, 2025

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : University of Colorado, Denver

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Costas Hadjipanayis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patien...

                            Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Brain Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 02, 2025

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Costas Hadjipanayis

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

                            Details : Gleolan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 07, 2023

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Icahn School of Medicine at Mount Sinai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial

                            Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 01, 2021

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Icahn School of Medicine at Mount Sinai

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed

                            NX Development Corp

                            U.S.A arrow
                            ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma

                            Details : Aminolevulinic Acid HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Meningioma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2020

                            Lead Product(s) : Aminolevulinic Acid HCl

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth